Ushbu ish iqtibos qilgan ishlar

361 ta ish

Ish: Epigenetic mechanisms and next-gen editing platforms in hematology: From molecular basis to therapeutic frontiers

1. Unveiling the potential of CLL-1: a promising target for AML therapy

   Hamed Soleimani Samarkhazan, Sara Zehtabcheh, Hamideh Rahmani Seraji +4

   Sharh maqola20256 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.109473

2. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

   Enli Liu, David Marín, Pinaki P. Banerjee +24

   Maqola20206 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.312682

3. Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53

   Leila Rajabi, Mostafa Ebrahimdoost, Seyed Amin Mohammadi +3

   Maqola20255 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.109472

4. Modified lentiviral globin gene therapy for pediatric β0/β0 transfusion-dependent β-thalassemia: A single-center, single-arm pilot trial

   Shiqi Li, Sikai Ling, Dawei Wang +17

   Maqola20245 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.312835

5. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

   Levi J. Rupp, Kathrin Schumann, Kole T. Roybal +4

   Maqola20174 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.020478

6. Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis

   Aziz Kubaev, Fadhil Faez Sead, Mohammad Pirouzbakht +6

   Sharh maqolaExtracellular vesicles in diseaseJournal of Liposome Research20254 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.109475

7. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression

   Lei S. Qi, Matthew H. Larson, Luke A. Gilbert +4

   Maqola20133 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.051601

8. Delivering CRISPR: a review of the challenges and approaches

   Christopher A. Lino, Jason C. Harper, James P. Carney +1

   Sharh maqola20183 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.051686

9. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

   Stephen J. Schuster, Michael Bishop, Constantine S. Tam +21

   Maqola20183 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296843

10. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner +32

    Maqola20183 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.312621

11. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

    Kevin Pan, Hizra Farrukh, Veera Chandra Sekhar Reddy Chittepu +3

    Sharh maqola20223 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.312769

12. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

    Yanfang Fu, Jennifer A Foden, Cyd Khayter +4

    Maqola20132 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.051539

13. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage

    Nicole M. Gaudelli, Alexis C. Komor, Holly A. Rees +4

    Maqola20172 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.051667

14. The CRISPR tool kit for genome editing and beyond

    Mazhar Adli

    Sharh maqola20182 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.051685

15. TRAPT: a multi-stage fused deep learning framework for predicting transcriptional regulators based on large-scale epigenomic data

    Guorui Zhang, Chao Song, Mingxue Yin +6

    Maqola20252 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.065083

16. CRISPR-engineered T cells in patients with refractory cancer

    Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38

    Maqola20202 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.102870

17. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

    Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech +17

    Maqola20232 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.102947

18. Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy

    Rajkumar Prabhakaran, Rajkumar Thamarai, Sivabalan Sivasamy +6

    Sharh maqola20242 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.112341

19. “Galectin-9: A double-edged sword in Acute Myeloid Leukemia”

    Omolbanin Sargazi-Aval, Ali Ahmadi, Ali Jihad Hemid Al-Athari +5

    Sharh maqola20252 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.138194

20. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies

    Sara Zehtabcheh, Hamed Soleimani Samarkhazan, Marjan Asadi +3

    Sharh maqola20252 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.138195

21. C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia

    Hamed Soleimani Samarkhazan, Sara Zehtabcheh, Sajjad Peyvasteh +1

    Sharh maqola20252 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.138196

22. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation

    Ashok Kumar Bishoyi, Sina Nouri, Ahmed Hussen +3

    Sharh maqola20252 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.138197

23. Non-homologous DNA end joining and alternative pathways to double-strand break repair

    Howard H. Chang, Nicholas R. Pannunzio, Noritaka Adachi +1

    Sharh maqola20172 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.194009

24. Epigenetic Therapeutics: A New Weapon in the War Against Cancer

    Nita Ahuja, Anup Sharma, Stephen B. Baylin

    Sharh maqola20162 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.204059

25. The Long Noncoding RNA MEG3 and its Target miR-147 Regulate JAK/STAT Pathway in Advanced Chronic Myeloid Leukemia

    Zi-ye Li, Lin Yang, Xiaojun Liu +3

    Maqola20182 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.224072